- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04108104
Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects (COCKTAIL)
Double-blind, Randomised, Parallel-group, Three-arm, Dose Range, Placebo-controlled, Proof-of-concept Study to Evaluate the Efficacy, Tolerability and Safety of a Combination of Cypropheptadine and Prazosin on Alcohol Consumption in Patients With Severe Alcohol Use Disorder
Double-blind randomised, parallel-group, three-arm, multicentre, placebo-controlled study The primary objective is to demonstrate the superiority of the combination of Periactine® (cyproheptadine 8 mg/day or 12 mg/day) and Alpress® (prazosin 5 mg/day or 10 mg/day) over placebo on the reduction of the total alcohol consumption (TAC), in alcohol-dependent patients.
180 patients will be randomised into the two treatment groups (N=60 in the low-dose group and N=60 in the high-dose group) and the placebo group (N=60).
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Abbeville, France
- Centre Hospitalier d'Abbeville
-
Agen, France
- Centre d'Addictologie "Pierre-Fouquet" - CHD La Candélie
-
Astillé, France
- clinique de la Bréhonnière
-
Bayonne, France
- Centre de Soins, d'Accompagnement et de Prévention en addictologie Bizia
-
Bayonne, France
- Centre Hospitalier de la Côte Basque - Service d'addictologie
-
Bersée, France
- Cabinet Médical
-
Brest, France
- CHRU Brest - Hôpital Cavale Blanche
-
Brest, France
- HIA Clermont Tonnerre
-
Bron, France
- Service Universitaire d'Addictologie de Lyon - Centre Hospitalier Le Vinatier
-
Clermont-Ferrand, France
- Centre Hospitalier Universitaire de Clermont-Ferrand
-
Créteil, France
- Centre Hospitalier Intercommunal de Créteil - Service Hépato-Gastro-entérologie
-
Dijon, France
- Centre Hospitalier Universitaire de Dijon - Service d'addictologie
-
La Couronne, France
- Centre Hospitalier Camille Claudel
-
La Rochelle, France
- Centre Hospitalier de La Rochelle
-
Le Puy-en-Velay, France
- Centre Hospitalier Emile-Roux
-
Limoges, France
- Centre hospitalier Esquirol - Pôle d'addictologie en Limousin
-
Lyon, France
- Centre Hospitalier Universitaire de Lyon - Hôpital de la Croix Rousse
-
Marseille, France
- CHU Provences-Alpes Côte d'Azur Hôpital Publique
-
Marseille, France
- Clinique Saint Barnabé
-
Montpellier, France
- Centre Hospitalier Régional Universitaire Saint Eloi - Service d'addictologie et complications somatiques
-
Nancy, France
- Hôpital St-Julien
-
Nantes, France
- Centre Hospitalier Universitaire de Nantes - site Hôtel-Dieu
-
Nice, France
- Centre Hospitalier universitaire de Nice - Hôpital Archet II
-
Nîmes, France
- Hôpital Universitaire Carémeau
-
Orléans, France
- Centre Hospitalier Régional d'Orléans - Hôpital La Source - Service d'hépato-gastro-entérologie et oncologie digestive
-
Orléans, France
- Centre Médico-Psychologique Saint-Marc
-
Paris, France
- Centre Hospitalier Sainte-Anne
-
Paris, France
- Hôpital Fernand-Widal
-
Pau, France
- Centre Hospitalier de Pau - Unité d'addictologie
-
Rennes, France
- Centre Hospitalier Universitaire de Rennes - Hôpital Pontchaillou - Centre hépato-digestif
-
Saint-Martin-d'Hères, France
- Centre Ambulatoire de Santé Mentale
-
Saint-Nazaire, France
- Centre Hospitalier de Saint-Nazaire
-
Saint-Rémy, France
- Association Hospitalière de Bourgogne Franche-Comté
-
Tours, France
- cabinet médical du Dr El-Ayoubi
-
Épagny, France
- Centre Hospitalier Annecy Genevois
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Severe alcohol use disorder
- High-risk alcohol consumption
Exclusion Criteria:
- Patient with orthostatic hypotension
- Patient with hypotension
- History of uncontrolled hypertension
- Patient at risk for urinary retention associated with urethroprostatic disorders
- Patient with a clinically-active malignancy
- Patient with a confirmed cirrhosis
- History of bronchial asthma
- History of uncontrolled hyperthyroidism
- History of cardiovascular disease not under control
- Severe psychiatric disorder
- History of alcohol withdrawal syndrome
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low-dose group
Periactine® (Cyproheptadine 8 mg/day; two times 4 mg: morning and evening) and Alpress® (5 mg once a day slow-release: evening administration).
|
3-month treatment
Other Names:
3-month treatment
Other Names:
|
Experimental: High-dose group
Periactine® (Cyproheptadine 12 mg/day; three times 4 mg: morning, noon and evening) and Alpress® (10 mg [2 tablets of 5 mg] once a day slow-release: evening administration)
|
3-month treatment
Other Names:
3-month treatment
Other Names:
|
Placebo Comparator: Placebo group
Placebo of Periactine® (three times per day: morning, noon and evening) and placebo of Alpress® (once a day: evening)
|
3-month treatment
Other Names:
3-month treatment
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change in the mean quantity of alcohol consumed per day in the three groups
Time Frame: weeks 9 to 12
|
weeks 9 to 12
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Alain Puech, Kinnov Therapeutics
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Mental Disorders
- Chemically-Induced Disorders
- Drinking Behavior
- Alcohol-Related Disorders
- Substance-Related Disorders
- Alcohol Drinking
- Alcoholism
- Physiological Effects of Drugs
- Adrenergic Antagonists
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Antihypertensive Agents
- Gastrointestinal Agents
- Dermatologic Agents
- Serotonin Agents
- Serotonin Antagonists
- Anti-Allergic Agents
- Histamine H1 Antagonists
- Histamine Antagonists
- Histamine Agents
- Antipruritics
- Adrenergic alpha-1 Receptor Antagonists
- Adrenergic alpha-Antagonists
- Prazosin
- Cyproheptadine
Other Study ID Numbers
- KT-100-001
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Use Disorder
-
Washington State UniversityRecruitingNicotine Use Disorder | Alcohol Use Disorder (AUD)United States
-
University of North Carolina, Chapel HillCompletedAlcohol Use Disorder, Mild | Alcohol Use Disorder, ModerateUnited States
-
Université du Québec à Trois-RivièresCompletedAlcohol Use, Unspecified | Alcohol Use Disorder, MildCanada
-
Woebot HealthStanford UniversityCompletedSubstance Use Disorders | Alcohol Use Disorder (AUD)United States
-
Medical University of South CarolinaNational Institute on Alcohol Abuse and Alcoholism (NIAAA); National Institutes...RecruitingAlcohol Drinking | Substance Use | Alcohol Use Disorder | Drinking, Alcohol | Alcohol Use Disorder (AUD)United States
-
Kaiser PermanenteNORC at the University of Chicago; Agency for Healthcare Research and Quality... and other collaboratorsCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Central Institute of Mental Health, MannheimNot yet recruitingAlcohol Use Disorder (AUD)Germany
-
Massachusetts General HospitalMbarara University of Science and TechnologyCompletedAlcohol Use Disorder (AUD)Uganda
-
ITAB - Institute for Advanced Biomedical TechnologiesNot yet recruitingNeurobiological Effects of Transcranial Direct Current Stimulation Treatment in Alcohol Use DisorderAlcohol Dependence | Alcohol-Related Disorders | Substance Use Disorders | Drug Abuse | Mental Disorder | Alcohol Abuse | Alcohol Use Disorder (AUD)
Clinical Trials on Cyproheptadine
-
Shirley Ryan AbilityLabEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsActive, not recruiting
-
University of South FloridaNational Cancer Institute (NCI)Terminated
-
University of South FloridaNational Cancer Institute (NCI)TerminatedLymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Malnutrition | Weight Changes
-
Ciusss de L'Est de l'Île de MontréalNot yet recruitingCOVID-19 Pneumonia | Serotonin Syndrome | Platelet Dysfunction | Viral Pneumonia
-
Laval UniversityCanadian Institutes of Health Research (CIHR)RecruitingIschemic Mitral RegurgitationCanada
-
Ciusss de L'Est de l'Île de MontréalCovid-19 Early Treatment FundNot yet recruitingSerotonin Syndrome | Platelet Dysfunction | Viral Pneumonia
-
Kinnov TherapeuticsNot yet recruitingAlcohol Use Disorder
-
University of OxfordEnrolling by invitation
-
University of South FloridaNational Cancer Institute (NCI)CompletedLymphoma | Unspecified Childhood Solid Tumor, Protocol Specific | Myelodysplastic Syndromes | Leukemia | Brain Tumor | Cachexia | Myelodysplastic/Myeloproliferative Diseases | Central Nervous System TumorsUnited States, Canada, Puerto Rico
-
Vanderbilt University Medical CenterEnrolling by invitation